Advanced Triple Negative Breast Cancer Clinical Trials

18 clinical trials for Advanced Triple Negative Breast Cancer across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. — RECRUITING · PHASE2
• A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer — RECRUITING · PHASE2
• Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer — RECRUITING · PHASE1
• Open-Label study of bevacizumab (Avastin®) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer — COMPLETED · PHASE4
• Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) — NOT_YET_RECRUITING · PHASE1
• Phase II study to improve sacituzumab govitecan tolerance with atropine in patients with advanced triple-negative and hormone receptor-positive/HER2-negative breast cancer (The SATROPIN Study). — NOT_YET_RECRUITING · PHASE2
• A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer “TRIFOUR study” — OTHER · PHASE2
• Tier Palliative Care For Patients With Advanced Heart Failure or Cancer — NOT_YET_RECRUITING · NA
• Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer — NOT_YET_RECRUITING · PHASE2
• RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVALUMAB/NAB-PACLITAXEL: THE ATRiBRAVE TRIAL — TERMINATED · PHASE2
• First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. — NOT_YET_RECRUITING · PHASE2
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer — NOT_YET_RECRUITING · PHASE2
• A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies — TERMINATED · PHASE1
• A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors — TERMINATED · PHASE1
• Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer — OTHER · PHASE1
• Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer — COMPLETED · PHASE2
• A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer — WITHDRAWN · PHASE1
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients — WITHDRAWN · PHASE1

Refine this search